In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA panel gives thumbs up to Chelsea's Northera, despite lack of data

This article was originally published in Scrip

Executive Summary

Chelsea Therapeutics on 23 February persuaded a panel of advisers to the US FDA to back Northera (droxidopa) as a therapy to improve symptoms of neurogenic orthostatic hypotension (NOH), a chronic disorder caused by a deficient release of norepinephrine, which results in a sudden drop in blood pressure when a person goes from a supine position to standing.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC016368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel